您的位置:首页>>分析化学>>脂类分析标准品>>1523 53674581-0 N-十七烷酰神经酰胺三己糖苷 N-Heptadecanoyl ceramide trihexoside
Cat. Number
1523
Chemical Name
1523 53674581-0 N-十七烷酰神经酰胺三己糖苷 N-Heptadecanoyl ceramide trihexoside
CAS Number
53674581-0
Mol. Formula
C53H99NO18
Mol. Weight
1038
Qty 1
500µg
Appearance
solid
Application Notes
98+%,TLC; identity confirmed by MS
Synonym
N-C17:0-Ceramide trihexoside; N-Heptadecanoyl globotriaosylceramide
Solubility
DMSO, hot methanol, chloroform/methanol, 2:1
Storage condition
-20℃
References

Application Notes:

This product is a well-defined CTH containing the uncommon heptadecanoic acid acylated to the ceramide making it ideal as an internal standard and for biological studies.1 Ceramide trihexoside (CTH) is a glycosphingolipid found mostly in mammalian cell membranes. It is involved in cellular signaling and has been identified as a receptor for various toxins including shiga toxins and shiga-like toxins.2 Some toxins, such as veratoxins from Escherichia coli, require specific fatty acids on the ceramide portion of CTH to show affinity in binding. An accumulation of CTH in the cellular membranes due to a lack of alpha-galactosidase to convert it into lactosyl ceramide results in Fabry disease.3 This product can be used as an excellent standard for the identification of CTH in Fabry disease by HPLC4 and mass spectrometry. An inability to convert CTH to globoside due to mutations in the gene sequence leads to the Pk blood group phenotype. It appears that under certain conditions CTH can enhance anticoagulant activity. CTH has also been studied as a tool to investigate lymphocyte activation.5

References: 
1. M. Fuller et al. “Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes” Clinical Chemistry, Vol. 51 pp. 688-694, 2005 
2. S. Ashkenazi and T. G. Cleary, “Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.” J Clin Microbio. June; 27(6): 1145-1150, 1989 
3. S. Bekri, O. Lidove, R. Jaussaud, B. Knebelmann, F. Barbey. "The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature". Cardiovasc Hematol Agents Med Chem 4 (4): 289–97, October 2006 
4. J. E. Groener, B. J. Poorthuis, S. Kuiper, M. T. Helmond, C. E. Hollak, J. M. Aerts. “HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.” Clin Chem., Apr;53(4):742-7, 2007. Epub Mar 1 2007 
5. C. Menge, I. Stamm, M. Wuhrer, R. Geyer, L. H. Wieler, G. Baljer. “Globotriaosylceramide (Gb(3)/CD77) is synthesized and surface expressed by bovine lymphocytes upon activation in vitro.” Vet Immunol Immunopathol., Nov;83(1-2):19-36, 2001

在线咨询 联系方式 二维码

服务热线

021-60498804

扫一扫,关注我们